Investors with over $100k losses in Park Ha Biological can step forward as lead plaintiffs in a securities lawsuit reiterated by Rosen Law Firm
Executive summary: Rosen Law Firm issued a press release reminding investors who bought Park Ha Biological Technology (PHH/BYAH) securities between Dec 27 2024 and July 8 2025 and incurred losses over $100k that they may serve as lead plaintiffs in the ongoing securities class action. The reminder sustains pressure on Park Ha Biological, potentially increasing legal costs and affecting investor confidence, while offering affected shareholders a path to pursue recovery of their losses.
Who is involved: Rosen Law Firm (plaintiffs’ counsel), Park Ha Biological Technology Co., Ltd. (ticker PHH/BYAH), and investors with losses exceeding $100,000 in the specified class period.
Likely next: Interested investors must file lead plaintiff motions by the September 28, 2026 deadline highlighted in prior alerts; the court will then consider any lead plaintiff applications and may proceed with class certification or settlement discussions.
Rosen Law Firm’s reminder highlights that purchasers of Park Ha Biological Technology Co., Ltd. (NASDAQ: PHH/BYAH) shares between December 27, 2024 and July 8, 2025 who suffered losses exceeding $100,000 may seek to lead the class action. The notice reiterates earlier alerts about a pending September 28, 2026 deadline for lead plaintiff applications and references allegations that the company’s low‑float structure facilitated a pump‑and‑dump scheme that erased more than $1 billion in market cap when the stock collapsed 93% in a single session on July 8, 2025. While the announcement does not introduce new facts, it keeps the litigation alive and signals continued legal exposure for the biotech firm.
Timeline
- — PHH, BYAH Deadline: PHH, BYAH Investors with Losses in Excess of $100K Have Opportunity to Lead Park Ha Biological Technology Co., Ltd. Securities Lawsuit (PR Newswire)
Analysis — what this means
Likely next events
- Lead plaintiff application deadline: September 28, 2026 (per Levi & Korsinsky deadline alert)
Sectors affected
- Biotechnology (Park Ha Biological Technology)
Regulatory implications
- Potential SEC scrutiny under Sections 11 and 12 of the Securities Act, which are central to the allegations
Historical parallels
- 2020 Luckin Coffee fabricated sales scandal that triggered a sharp share price collapse and subsequent securities litigation
Key entities
Sources
Open the full interactive case file on Beyond →